|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US5670527A
(en)
|
1993-07-16 |
1997-09-23 |
Smithkline Beecham Corporation |
Pyridyl imidazole compounds and compositions
|
|
US5593992A
(en)
|
1993-07-16 |
1997-01-14 |
Smithkline Beecham Corporation |
Compounds
|
|
US6369068B1
(en)
|
1995-06-07 |
2002-04-09 |
Smithkline Beecham Corporation |
Amino substituted pyrimidine containing compounds
|
|
IL118544A
(en)
|
1995-06-07 |
2001-08-08 |
Smithkline Beecham Corp |
History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
|
|
AP9700912A0
(en)
|
1996-01-11 |
1997-01-31 |
Smithkline Beecham Corp |
Novel cycloalkyl substituted imidazoles
|
|
ZA97175B
(en)
|
1996-01-11 |
1997-11-04 |
Smithkline Beecham Corp |
Novel substituted imidazole compounds.
|
|
EP0883402A4
(en)
|
1996-01-11 |
1999-08-11 |
Smithkline Beecham Corp |
NEW CYCLOALKYL-SUBSTITUTED IMIDAZOLES
|
|
US6372741B1
(en)
|
1996-03-08 |
2002-04-16 |
Smithkline Beecham Corporation |
Use of CSAID™ compounds as inhibitors of angiogenesis
|
|
US6218136B1
(en)
|
1996-03-12 |
2001-04-17 |
Smithkline Beecham Corporation |
Methods of the identification of pharmaceutically active compounds
|
|
US6096748A
(en)
|
1996-03-13 |
2000-08-01 |
Smithkline Beecham Corporation |
Pyrimidine compounds useful in treating cytokine mediated diseases
|
|
EP0889888A4
(en)
|
1996-03-25 |
2003-01-08 |
Smithkline Beecham Corp |
NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM
|
|
EP0889887A4
(en)
|
1996-03-25 |
2003-06-11 |
Smithkline Beecham Corp |
TREATMENT OF CENTRAL NERVOUS SYSTEM INJURIES
|
|
WO1998007425A1
(en)
|
1996-08-21 |
1998-02-26 |
Smithkline Beecham Corporation |
Imidazole compounds, compositions and use
|
|
US6096753A
(en)
|
1996-12-05 |
2000-08-01 |
Amgen Inc. |
Substituted pyrimidinone and pyridone compounds and methods of use
|
|
US6147080A
(en)
|
1996-12-18 |
2000-11-14 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of p38
|
|
US5965583A
(en)
|
1997-04-24 |
1999-10-12 |
Ortho-Mcneil Pharmaceutical, Inc. |
Substituted imidazoles useful in the treatment of inflammatory disease
|
|
US6514977B1
(en)
|
1997-05-22 |
2003-02-04 |
G.D. Searle & Company |
Substituted pyrazoles as p38 kinase inhibitors
|
|
AU7966198A
(en)
|
1997-06-13 |
1998-12-30 |
Smithkline Beecham Corporation |
Novel pyrazole and pyrazoline substituted compounds
|
|
EP0994870A4
(en)
|
1997-06-19 |
2002-10-23 |
Smithkline Beecham |
NEW IMIDAZOLE COMPOUNDS SUBSTITUTED BY AN ARYLOXYREST
|
|
US6093742A
(en)
|
1997-06-27 |
2000-07-25 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of p38
|
|
TW517055B
(en)
|
1997-07-02 |
2003-01-11 |
Smithkline Beecham Corp |
Novel substituted imidazole compounds
|
|
AR016294A1
(es)
|
1997-07-02 |
2001-07-04 |
Smithkline Beecham Corp |
Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
|
|
GB9721437D0
(en)
|
1997-10-10 |
1997-12-10 |
Glaxo Group Ltd |
Heteroaromatic compounds and their use in medicine
|
|
BR9812944A
(pt)
|
1997-10-20 |
2000-08-08 |
Hoffmann La Roche |
Inibidores bicìclicos da cinase
|
|
JP2002515891A
(ja)
|
1997-12-19 |
2002-05-28 |
スミスクライン・ビーチャム・コーポレイション |
新規なピペリジン含有化合物
|
|
US6162613A
(en)
|
1998-02-18 |
2000-12-19 |
Vertex Pharmaceuticals, Inc. |
Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases
|
|
HRP20000724A2
(en)
|
1998-05-05 |
2001-06-30 |
Hoffmann La Roche |
Pyrazole derivatives as p-38 map kinase inhibitors
|
|
US6316466B1
(en)
|
1998-05-05 |
2001-11-13 |
Syntex (U.S.A.) Llc |
Pyrazole derivatives P-38 MAP kinase inhibitors
|
|
MY132496A
(en)
|
1998-05-11 |
2007-10-31 |
Vertex Pharma |
Inhibitors of p38
|
|
JP2002516322A
(ja)
|
1998-05-22 |
2002-06-04 |
スミスクライン・ビーチャム・コーポレイション |
新規２−アルキル置換イミダゾール化合物
|
|
US6448257B1
(en)
|
1998-05-22 |
2002-09-10 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
|
US6589954B1
(en)
|
1998-05-22 |
2003-07-08 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
|
US6340685B1
(en)
|
1998-05-22 |
2002-01-22 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
|
KR100605140B1
(ko)
|
1998-05-22 |
2006-07-28 |
싸이오스 인크 |
심장병 및 다른 질병을 치료하기 위한 헤테로 고리 화합물및 그 치료 방법
|
|
US6867209B1
(en)
|
1998-05-22 |
2005-03-15 |
Scios, Inc. |
Indole-type derivatives as inhibitors of p38 kinase
|
|
JP2002517486A
(ja)
|
1998-06-12 |
2002-06-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ｐ３８のインヒビター
|
|
CA2341370A1
(en)
|
1998-08-20 |
2000-03-02 |
Smithkline Beecham Corporation |
Novel substituted triazole compounds
|
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
|
JP2002526482A
(ja)
|
1998-09-18 |
2002-08-20 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ｐ３８のインヒビター
|
|
US6649617B1
(en)
|
1998-10-07 |
2003-11-18 |
Smithkline Beecham Corporation |
Treatment for stroke management
|
|
DE69914357T2
(de)
|
1998-11-04 |
2004-11-11 |
Smithkline Beecham Corp. |
Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
|
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
|
DE60033028T2
(de)
|
1999-04-23 |
2007-11-15 |
Takeda Pharmaceutical Co. Ltd. |
5-pyridyl-1,3-azol-derivate, verfahren zu ihrer herstellung und ihre verwendung
|
|
JP2003500403A
(ja)
|
1999-05-21 |
2003-01-07 |
サイオス，インコーポレーテッド |
ｐ３８キナーゼのインヒビターとしてのインドール型誘導体
|
|
CA2374737C
(en)
|
1999-07-09 |
2008-02-12 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Novel process for synthesis of heteroaryl-substituted urea compounds
|
|
US6541477B2
(en)
|
1999-08-27 |
2003-04-01 |
Scios, Inc. |
Inhibitors of p38-a kinase
|
|
BR0014041A
(pt)
|
1999-09-17 |
2003-07-15 |
Smithkline Beecham Corp |
Utilização de csaids em infecção por rinovìrus
|
|
CZ20021743A3
(cs)
|
1999-10-21 |
2002-08-14 |
F. Hoffmann-La Roche Ag |
Bicyklické dusíkové heterocykly substituované alkylaminoskupinou jako inhibitory P38 proteinkinázy
|
|
AU776250B2
(en)
|
1999-10-21 |
2004-09-02 |
F. Hoffmann-La Roche Ag |
Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
|
|
AU1626001A
(en)
|
1999-11-23 |
2001-06-04 |
Smithkline Beecham Corporation |
3,4-dihydro-(1h)-quinazolin-2-ones and their use as csbp/p38 kinase inhibitors
|
|
EP1233950B1
(en)
|
1999-11-23 |
2005-10-05 |
Smithkline Beecham Corporation |
3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
|
|
JP2003514900A
(ja)
|
1999-11-23 |
2003-04-22 |
スミスクライン・ビーチャム・コーポレイション |
ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
|
|
ATE281439T1
(de)
|
1999-11-23 |
2004-11-15 |
Smithkline Beecham Corp |
3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
|
|
EP1246823A1
(en)
|
1999-12-28 |
2002-10-09 |
Pharmacopeia, Inc. |
Pyrimidine and triazine kinase inhibitors
|
|
US6906067B2
(en)
|
1999-12-28 |
2005-06-14 |
Bristol-Myers Squibb Company |
N-heterocyclic inhibitors of TNF-α expression
|
|
AU2001241927A1
(en)
|
2000-02-28 |
2001-09-12 |
Scios Inc. |
Inhibitors of p38-alpha kinase
|
|
AR030053A1
(es)
|
2000-03-02 |
2003-08-13 |
Smithkline Beecham Corp |
1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
|
|
US6565880B2
(en)
|
2000-07-24 |
2003-05-20 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
|
|
PE20020506A1
(es)
|
2000-08-22 |
2002-07-09 |
Glaxo Group Ltd |
Derivados de pirazol fusionados como inhibidores de la proteina cinasa
|
|
CA2420286A1
(en)
|
2000-08-31 |
2002-03-07 |
F. Hoffmann-La Roche Ag |
7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
|
|
CA2420122A1
(en)
|
2000-08-31 |
2002-03-07 |
F. Hoffmann-La Roche Ag |
7-oxo pyridopyrimidines
|
|
JP2004511542A
(ja)
|
2000-10-19 |
2004-04-15 |
スミスクライン・ビーチャム・コーポレイション |
煙の吸入の治療のためのｐ３８阻害剤の使用
|
|
AU2002248269A1
(en)
|
2000-10-19 |
2002-08-12 |
Smithkline Beecham Corporation |
Use of p38 inhibitors for the treatment of inflammation-enhanced cough
|
|
CN100525768C
(zh)
|
2000-10-23 |
2009-08-12 |
史密丝克莱恩比彻姆公司 |
新化合物
|
|
GEP20063915B
(en)
|
2000-11-17 |
2006-09-11 |
Bristol Myers Squibb Co |
PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
|
|
EP1339708A2
(en)
|
2000-11-20 |
2003-09-03 |
Scios Inc. |
Indole-type inhibitors of p38 kinase
|
|
DE60125980T2
(de)
|
2000-11-20 |
2007-10-25 |
Scios Inc., Sunnyvale |
P38kinase-inhibitoren vom piperidin/piperazin-typ
|
|
EP1341782A2
(en)
|
2000-11-20 |
2003-09-10 |
Scios Inc. |
Inhibitors of p38 kinase
|
|
US20020165286A1
(en)
|
2000-12-08 |
2002-11-07 |
Hanne Hedeman |
Dermal anti-inflammatory composition
|
|
JP2004521892A
(ja)
|
2000-12-20 |
2004-07-22 |
メルク エンド カムパニー インコーポレーテッド |
（ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤
|
|
DE60206363T2
(de)
|
2001-02-12 |
2006-07-06 |
F. Hoffmann-La Roche Ag |
6-substituierte pyridopyrimidine
|
|
AU2002305942B2
(en)
|
2001-02-28 |
2006-10-26 |
Onconova Therapeutics, Inc. |
Method for protecting cells and tissues from ionizing radiation toxicity with Alpha, Beta unsaturated aryl sulfones
|
|
HUP0303415A2
(hu)
|
2001-03-09 |
2004-01-28 |
Pfizer Products Inc. |
Triazolopiridinek, mint gyulladásgátló anyagok és ezeket tartalmazó gyógyszerkészítmények
|
|
AP2002002460A0
(en)
|
2001-03-09 |
2002-06-30 |
Pfizer Prod Inc |
Novel benzimidazole anti-inflammatory compounds.
|
|
WO2002076985A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
|
WO2002076984A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
|
WO2002076463A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
|
WO2002076954A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
|
WO2002076396A2
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
|
DE60205974T2
(de)
|
2001-04-04 |
2006-06-29 |
Pfizer Products Inc., Groton |
Neue Benzotriazole mit entzündungshemmender Wirkung
|
|
JP4660067B2
(ja)
|
2001-04-24 |
2011-03-30 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗血管新生剤とＴＮＦαとを用いる組合せ療法
|
|
WO2002090360A1
(en)
|
2001-05-10 |
2002-11-14 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
|
WO2002092087A1
(en)
|
2001-05-11 |
2002-11-21 |
Vertex Pharmaceuticals Incorporated |
2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
|
|
SK287857B6
(sk)
|
2001-05-24 |
2012-01-04 |
Eli Lilly And Company |
Novel pyrrole derivatives as pharmaceutical agents
|
|
ATE415162T1
(de)
|
2001-06-11 |
2008-12-15 |
Vertex Pharma |
Isochinolin-inhibitoren von p38
|
|
WO2003000682A1
(en)
|
2001-06-25 |
2003-01-03 |
Merck & Co., Inc. |
(pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
|
|
AU2002316421B2
(en)
|
2001-06-26 |
2008-05-15 |
Bristol-Myers Squibb Company |
N-heterocyclic inhibitors of TNF-ALPHA expression
|
|
WO2003005999A2
(en)
|
2001-07-11 |
2003-01-23 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediated diseases
|
|
WO2003015828A1
(en)
|
2001-08-20 |
2003-02-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and a cyclodextrin
|
|
PL373115A1
(en)
|
2001-08-30 |
2005-08-08 |
F.Hoffmann-La Roche Ag |
Aminopyrrole compounds as antiinflammatory agents
|
|
EP1429779A2
(en)
|
2001-09-21 |
2004-06-23 |
Merck & Co., Inc. |
Androstanes as androgen receptor modulators
|
|
US7205275B2
(en)
|
2001-10-11 |
2007-04-17 |
Amgen Inc. |
Methods of treatment using specific binding agents of human angiopoietin-2
|
|
AU2002329570A1
(en)
|
2001-10-12 |
2003-01-30 |
Pfizer Products Inc. |
Method of monitoring neuroprotective treatment
|
|
GB0124928D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124936D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124939D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124938D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124931D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124941D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124932D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB0124933D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
US20040235728A1
(en)
|
2001-11-08 |
2004-11-25 |
Stoch Selwyn Aubrey |
Compositions and methods for treating osteoporosis
|
|
WO2003041644A2
(en)
|
2001-11-09 |
2003-05-22 |
Scios Inc. |
Method to treat cystic fibrosis
|
|
EP1461758A4
(en)
|
2001-12-05 |
2005-10-05 |
Vertex Pharma |
CRYSTAL STRUCTURE OF AN MITOGENIC ACTIVATED PROTEIN, KINASE-ACTIVATED PROTEIN, KINASE-2 AND BINDING POCKETS THEREFOR
|
|
EP1455791A1
(en)
|
2001-12-11 |
2004-09-15 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Method for administering birb 796 bs
|
|
US20050202090A1
(en)
|
2002-01-03 |
2005-09-15 |
Clarke Allan J. |
Novel pharmaceutical dosage forms and method for producing same
|
|
WO2003059293A2
(en)
|
2002-01-15 |
2003-07-24 |
Merck & Co., Inc. |
17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators
|
|
DE10203753A1
(de)
|
2002-01-31 |
2003-08-14 |
Boehringer Ingelheim Pharma |
Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
|
DE10203741A1
(de)
|
2002-01-31 |
2003-08-14 |
Boehringer Ingelheim Pharma |
Neue Fluorencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
|
DE10203749A1
(de)
|
2002-01-31 |
2003-08-14 |
Boehringer Ingelheim Pharma |
Neue Anticholinergika, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
|
US20040023961A1
(en)
|
2002-02-11 |
2004-02-05 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenisis inhibiting activity
|
|
ATE375980T1
(de)
|
2002-02-12 |
2007-11-15 |
Smithkline Beecham Corp |
Nicotinamide und deren verwendung als p38 inhibitoren
|
|
ES2314224T3
(es)
|
2002-03-07 |
2009-03-16 |
F. Hoffmann-La Roche Ag |
Inhibidores pirimidina y piridina biciclicos de p38 quinasa.
|
|
PL372920A1
(en)
|
2002-03-13 |
2005-08-08 |
Merck & Co,Inc. |
Fluorinated 4-azasteroid derivatives as androgen receptor modulators
|
|
US7101883B2
(en)
|
2002-03-18 |
2006-09-05 |
Bristol-Myers Squibb Company |
Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases
|
|
US6900208B2
(en)
|
2002-03-28 |
2005-05-31 |
Bristol Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
|
JP2006503802A
(ja)
|
2002-04-03 |
2006-02-02 |
エフ．ホフマン−ラ ロシュ アーゲー |
イミダゾ縮合化合物
|
|
CA2479520A1
(en)
|
2002-04-05 |
2003-10-16 |
Birgit Jung |
P38 kinase inhibitors for treating mucus hypersecretion_
|
|
US20030225089A1
(en)
|
2002-04-10 |
2003-12-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
|
|
DE10216339A1
(de)
|
2002-04-13 |
2003-10-23 |
Boehringer Ingelheim Pharma |
Neue Ester hydroxy-substituierter Stickstoffheterocyclen, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
|
AU2003229689A1
(en)
|
2002-04-15 |
2003-10-27 |
Glaxo Group Limited |
A method of identifying a modudator for a serine/theronine kinase
|
|
KR20040103972A
(ko)
|
2002-04-19 |
2004-12-09 |
스미스클라인 비참 코포레이션 |
신규 화합물
|
|
TW200306841A
(en)
|
2002-04-23 |
2003-12-01 |
Bristol Myers Squibb Co |
Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
|
|
PT1497019E
(pt)
|
2002-04-23 |
2015-09-10 |
Bristol Myers Squibb Co |
Compostos de pirrolotriazina anilina úteis como inibidores de quinase
|
|
US7388009B2
(en)
|
2002-04-23 |
2008-06-17 |
Bristol-Myers Squibb Company |
Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
|
|
GB0209891D0
(en)
|
2002-04-30 |
2002-06-05 |
Glaxo Group Ltd |
Novel compounds
|
|
CA2484173A1
(en)
|
2002-04-30 |
2003-11-13 |
Merck & Co., Inc. |
4-azasteroid derivatives as androgen receptor modulators
|
|
AU2003229305A1
(en)
|
2002-05-17 |
2003-12-02 |
Scios, Inc. |
TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
|
|
TW200400034A
(en)
|
2002-05-20 |
2004-01-01 |
Bristol Myers Squibb Co |
Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
|
|
AU2003239508A1
(en)
|
2002-05-21 |
2003-12-12 |
Bristol-Myers Squibb Company |
Indole compounds useful as impdh inhibitors
|
|
US7314873B2
(en)
|
2002-06-11 |
2008-01-01 |
Merck & Co., Inc. |
(Halo-benzo carbonyl)heterobi cyclic p38 linase inhibiting agents
|
|
ES2278170T3
(es)
|
2002-07-09 |
2007-08-01 |
BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG |
Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
|
|
EP1575506A4
(en)
|
2002-07-25 |
2008-04-23 |
Scios Inc |
METHOD FOR IMPROVING LUNG FUNCTION WITH TGF-BETA INHIBITORS
|
|
GB0217757D0
(en)
|
2002-07-31 |
2002-09-11 |
Glaxo Group Ltd |
Novel compounds
|
|
AU2003251661A1
(en)
|
2002-08-06 |
2004-02-25 |
F. Hoffmann-La Roche Ag |
6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
|
|
EP1549621A1
(en)
|
2002-08-08 |
2005-07-06 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
|
|
WO2004014900A1
(en)
|
2002-08-09 |
2004-02-19 |
Eli Lilly And Company |
Benzimidazoles and benzothiazoles as inhibitors of map kinase
|
|
US20040110755A1
(en)
|
2002-08-13 |
2004-06-10 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
|
|
JP2006500365A
(ja)
|
2002-08-14 |
2006-01-05 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
ｐ３８ＭＡＰキナーゼインヒビターを用いた抗凝固及び線維素溶解療法
|
|
WO2004019873A2
(en)
|
2002-08-29 |
2004-03-11 |
Scios Inc. |
Methods of promoting osteogenesis
|
|
US7012143B2
(en)
|
2002-08-30 |
2006-03-14 |
Dombroski Mark A |
Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
|
|
PA8579601A1
(es)
|
2002-08-30 |
2004-05-07 |
Pfizer Prod Inc |
Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
|
|
US7037923B2
(en)
|
2002-08-30 |
2006-05-02 |
Pfizer, Inc. |
Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
|
|
US7005523B2
(en)
|
2002-08-30 |
2006-02-28 |
Pfizer Inc. |
Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
|
|
WO2004020438A2
(en)
|
2002-08-30 |
2004-03-11 |
Pfizer Products Inc. |
Novel processes and intermediates for preparing triazolo-pyridines
|
|
US20040092547A1
(en)
|
2002-08-30 |
2004-05-13 |
Pfizer Inc |
Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
|
|
AU2003268464A1
(en)
|
2002-09-03 |
2004-03-29 |
Scios Inc. |
INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
|
|
EP1545535A4
(en)
|
2002-09-05 |
2008-06-04 |
Scios Inc |
TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE
|
|
WO2004021979A2
(en)
|
2002-09-06 |
2004-03-18 |
Smithkline Beecham Corporation |
PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
|
|
US7115644B2
(en)
|
2002-09-13 |
2006-10-03 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Heterocyclic compounds
|
|
EP1543001B1
(en)
|
2002-09-17 |
2007-08-15 |
Eli Lilly And Company |
Pyrazolopyridine derivatives as tgf beta signal transduction inhibitors for the treatment of cancer
|
|
KR20050053694A
(ko)
|
2002-09-27 |
2005-06-08 |
얀센 파마슈티카 엔.브이. |
3, 4-이치환된 피롤 및 염증 질환을 치료하기 위한 그의용도
|
|
US7041693B2
(en)
|
2002-10-04 |
2006-05-09 |
Bristol-Myers Squibb Company |
Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
|
|
US20050288299A1
(en)
|
2002-10-09 |
2005-12-29 |
Mavunkel Babu J |
Azaindole derivatives as inhibitors of p38 kinase
|
|
AU2003279230A1
(en)
|
2002-10-09 |
2004-05-04 |
Scios Inc. |
AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE
|
|
US7622592B2
(en)
|
2002-11-01 |
2009-11-24 |
Merck & Co., Inc. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
|
KR20050075028A
(ko)
|
2002-11-18 |
2005-07-19 |
에프. 호프만-라 로슈 아게 |
다이아지노피리미딘
|
|
DE10255040A1
(de)
|
2002-11-26 |
2004-06-03 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Carbaminsäureester mit anticholinerger Wirksamkeit
|
|
JP2006510654A
(ja)
|
2002-12-06 |
2006-03-30 |
サイオス・インコーポレーテツド |
糖尿病を処置する方法
|
|
WO2004069793A2
(en)
|
2003-01-28 |
2004-08-19 |
Bristol-Myers Squibb Company |
Novel 2-substituted cyclic amines as calcium sensing receptor modulators
|
|
JP2006516653A
(ja)
|
2003-02-05 |
2006-07-06 |
ブリストル−マイヤーズ スクイブ カンパニー |
キナーゼ阻害剤ピロロトリアジンの製造方法
|
|
RU2351590C2
(ru)
|
2003-02-10 |
2009-04-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ получения диариламина
|
|
US7205322B2
(en)
|
2003-02-12 |
2007-04-17 |
Bristol-Myers Squibb Company |
Thiazolidine compounds as calcium sensing receptor modulators
|
|
EP1601672B1
(en)
|
2003-02-14 |
2006-07-26 |
Pfizer Products Inc. |
Triazolo-pyridines as anti-inflammatory compounds
|
|
US7550480B2
(en)
|
2003-02-14 |
2009-06-23 |
Smithkline Beecham Corporation |
Compounds
|
|
US7468376B2
(en)
|
2003-02-27 |
2008-12-23 |
Palau Pharma, S.A. |
Pyrazolopyridine derivates
|
|
US7135575B2
(en)
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
|
US7521447B2
(en)
|
2003-03-03 |
2009-04-21 |
Array Biopharma Inc. |
P38 inhibitors and methods of use thereof
|
|
US7030112B2
(en)
|
2003-03-25 |
2006-04-18 |
Bristol-Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
|
GB0308185D0
(en)
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0308186D0
(en)
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0308201D0
(en)
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
|
CA2520785A1
(en)
|
2003-04-16 |
2004-10-28 |
F. Hoffmann-La Roche Ag |
Substituted 7-aza-quinazoline compounds
|
|
JP2006523638A
(ja)
|
2003-04-16 |
2006-10-19 |
エフ．ホフマン−ラ ロシュ アーゲー |
キナゾリン化合物
|
|
EP2385041B1
(en)
|
2003-05-01 |
2013-09-18 |
Bristol-Myers Squibb Company |
Pyrazole-amine compounds useful as kinase inhibitors
|
|
GB0320244D0
(en)
|
2003-05-06 |
2003-10-01 |
Aventis Pharma Inc |
Pyrazoles as inhibitors of tumour necrosis factor
|
|
CA2524409C
(en)
|
2003-05-07 |
2011-12-20 |
Merck & Co., Inc. |
Androgen receptor modulators and methods of use thereof
|
|
EP1633714B1
(en)
|
2003-06-04 |
2008-01-23 |
Pfizer Limited |
2-amino-pyridine derivatives as beta-2 adrenoreceptor agonists
|
|
PL2298743T3
(pl)
|
2003-06-26 |
2013-02-28 |
Novartis Ag |
Inhibitory kinaz P38 na bazie 5-członowych heterocykli
|
|
CA2530182A1
(en)
|
2003-06-30 |
2005-01-20 |
Merck & Co., Inc. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
|
US7696217B2
(en)
|
2003-06-30 |
2010-04-13 |
Merck Sharp & Dohme Corp. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
|
US20060234931A1
(en)
|
2003-07-17 |
2006-10-19 |
Biggs William H Iii |
Treatment of diseases with kinase inhibitors
|
|
GB0317484D0
(en)
|
2003-07-25 |
2003-08-27 |
Pfizer Ltd |
Nicotinamide derivatives useful as pde4 inhibitors
|
|
US20050020587A1
(en)
|
2003-07-25 |
2005-01-27 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
|
GB0317516D0
(en)
|
2003-07-25 |
2003-08-27 |
Pfizer Ltd |
Nicotinamide derivatives useful as PDE4 inhibitors
|
|
GB0317482D0
(en)
|
2003-07-25 |
2003-08-27 |
Pfizer Ltd |
Nicotinamide derivatives useful as pde4 inhibitors
|
|
US7153870B2
(en)
|
2003-07-25 |
2006-12-26 |
Pfizer Inc. |
Nicotinamide derivatives useful as PDE4 inhibitors
|
|
WO2005012875A2
(en)
|
2003-07-29 |
2005-02-10 |
Bristol-Myers Squibb Company |
Biomarkers of cyclin-dependent kinase modulation
|
|
GB0318814D0
(en)
|
2003-08-11 |
2003-09-10 |
Smithkline Beecham Corp |
Novel compounds
|
|
CL2004002050A1
(es)
|
2003-08-13 |
2005-06-03 |
Pharmacia Corp Sa Organizada B |
Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
|
|
CA2536293A1
(en)
|
2003-08-22 |
2005-03-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating copd and pulmonary hypertension
|
|
US20050053600A1
(en)
|
2003-09-09 |
2005-03-10 |
Lane Thomas E. |
Methods for treating rheumatoid arthritis
|
|
US7446110B2
(en)
|
2003-09-10 |
2008-11-04 |
Merck & Co., Inc. |
17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators
|
|
WO2005023761A2
(en)
|
2003-09-11 |
2005-03-17 |
Kemia, Inc. |
Cytokine inhibitors
|
|
WO2005032481A2
(en)
|
2003-09-30 |
2005-04-14 |
Scios Inc. |
Quinazoline derivatives as medicaments
|
|
WO2005032551A1
(en)
|
2003-09-30 |
2005-04-14 |
Scios Inc. |
TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE
|
|
JP2007507529A
(ja)
|
2003-09-30 |
2007-03-29 |
サイオス・インコーポレーテツド |
複素環式アミドおよびスルホンアミド
|
|
US7419978B2
(en)
|
2003-10-22 |
2008-09-02 |
Bristol-Myers Squibb Company |
Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
|
|
RU2348632C2
(ru)
|
2003-11-13 |
2009-03-10 |
Ф.Хоффманн-Ля Рош Аг |
Гидроксиалкилзамещенные пиридо-7-пиримидин-7-оны
|
|
EP1538201A1
(en)
|
2003-12-02 |
2005-06-08 |
F.Hoffmann-La Roche Ag |
Method for the recombinant production and purification of protein kinases
|
|
GB0329275D0
(en)
|
2003-12-18 |
2004-01-21 |
Merck Sharp & Dohme |
Therapeutic treatment
|
|
WO2005063715A1
(en)
|
2003-12-18 |
2005-07-14 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Polymorph of birb 796, a p38map kinase inhibitor
|
|
BRPI0417674A
(pt)
|
2003-12-18 |
2007-03-20 |
Pfizer Prod Inc |
método para tratar a inflamação aguda em animais, com inibidores de quinase map p38
|
|
US20060052390A1
(en)
|
2003-12-24 |
2006-03-09 |
Scios, Inc. |
Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
|
|
US20060079461A1
(en)
|
2003-12-24 |
2006-04-13 |
Scios, Inc. |
Treatment of multiple myeloma by inhibition of p38 MAP kinase
|
|
US20060058296A1
(en)
|
2003-12-24 |
2006-03-16 |
Scios, Inc. |
Treatment of osteolytic lesions associated with multiple myeloma by inhibition of p38 map kinase
|
|
MXPA06008157A
(es)
|
2003-12-24 |
2007-09-07 |
Johnson & Johnson |
Tratamiento de gliomas malignos con inhibidores de factor de crecimiento transformante-beta.
|
|
BRPI0507198A
(pt)
|
2004-01-30 |
2007-06-26 |
Merck Patent Gmbh |
derivados de bisariluréia
|
|
GB0402138D0
(en)
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0402140D0
(en)
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0402143D0
(en)
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0402137D0
(en)
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
|
TWI332003B
(en)
|
2004-01-30 |
2010-10-21 |
Lilly Co Eli |
Kinase inhibitors
|
|
EP1720862A1
(en)
|
2004-02-03 |
2006-11-15 |
Eli Lilly And Company |
Kinase inhibitors
|
|
US7652146B2
(en)
|
2004-02-06 |
2010-01-26 |
Bristol-Myers Squibb Company |
Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
|
|
TWI338004B
(en)
|
2004-02-06 |
2011-03-01 |
Bristol Myers Squibb Co |
Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
|
|
US20070191444A1
(en)
|
2004-02-26 |
2007-08-16 |
Hans-Peter Buchstaller |
Benzimidazolyl derivatives
|
|
RU2006134022A
(ru)
|
2004-02-27 |
2008-04-10 |
Ф.Хоффманн-Ля Рош Аг (Ch) |
Производные индазола и содержащие их фармацевтические композиции
|
|
CN1934111A
(zh)
|
2004-02-27 |
2007-03-21 |
霍夫曼-拉罗奇有限公司 |
杂芳基稠合的吡唑并衍生物
|
|
EP1574501A1
(en)
|
2004-03-11 |
2005-09-14 |
Pfizer Limited |
Quinolinone derivatives, pharmaceutical compositions containing them and their use
|
|
AU2005227192A1
(en)
|
2004-03-11 |
2005-10-06 |
Kythera Biopharmaceuticals, Inc. |
Compositions and methods for preventing and treating skin and hair conditions
|
|
EP1577291A1
(en)
|
2004-03-17 |
2005-09-21 |
Pfizer Limited |
Phenylethanolamine derivatives as beta-2 agonists
|
|
EP1577292A1
(en)
|
2004-03-17 |
2005-09-21 |
Pfizer Limited |
Phenylaminoethanol derivatives as beta2 receptor agonists
|
|
WO2005105091A1
(en)
|
2004-04-28 |
2005-11-10 |
Merck & Co., Inc. |
Fluorinated 4-azasteroids as androgen receptor modulators
|
|
WO2005110455A2
(en)
|
2004-05-13 |
2005-11-24 |
Intermune, Inc. |
Combination therapy for treating hepatitis virus infection
|
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
|
EP1609789A1
(en)
|
2004-06-23 |
2005-12-28 |
Eli Lilly And Company |
Ureido-pyrazole derivatives and their use as kinase inhibitors
|
|
PT1761520E
(pt)
|
2004-06-23 |
2008-09-15 |
Lilly Co Eli |
Inibidores de quinase
|
|
US7253167B2
(en)
|
2004-06-30 |
2007-08-07 |
Bristol-Myers Squibb Company |
Tricyclic-heteroaryl compounds useful as kinase inhibitors
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
TW200618803A
(en)
|
2004-08-12 |
2006-06-16 |
Bristol Myers Squibb Co |
Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
|
|
EA012119B1
(ru)
|
2004-08-12 |
2009-08-28 |
Пфайзер Инк. |
ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНСУЛЬФАНИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ p38 MAP КИНАЗЫ
|
|
JP2008510811A
(ja)
|
2004-08-25 |
2008-04-10 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体モジュレーター
|
|
US20070054916A1
(en)
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
|
AR055271A1
(es)
|
2004-10-05 |
2007-08-15 |
Smithkline Beecham Corp |
Compuesto del acido bifenil carboxilico, composicion farmaceutica que lo comprende, su uso para preparar esta ultima y proceso para prepararlo
|
|
WO2006040056A1
(en)
|
2004-10-13 |
2006-04-20 |
Merck Patent Gmbh |
Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
|
|
EP1809282B1
(en)
|
2004-10-18 |
2013-01-09 |
Amgen, Inc |
Thiadiazole compounds and methods of use
|
|
JP2008518968A
(ja)
|
2004-10-29 |
2008-06-05 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体モジュレーターとしてのｎ−（ピリジン−３−イル）−２−フェニルブタンアミド
|
|
WO2006048266A2
(en)
|
2004-11-04 |
2006-05-11 |
Roche Diagnostics Gmbh |
Gene expression profiling of leukemias with mll gene rearrangements
|
|
US20060258582A1
(en)
|
2004-11-04 |
2006-11-16 |
Scios, Inc. |
Method of treating myelodysplastic syndromes
|
|
WO2006051373A1
(en)
|
2004-11-12 |
2006-05-18 |
Pfizer Limited |
Compounds for the treatment of diseases
|
|
GB0425057D0
(en)
|
2004-11-12 |
2004-12-15 |
Pfizer Ltd |
L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide
|
|
US7495029B2
(en)
|
2004-11-16 |
2009-02-24 |
Merck & Co., Inc |
Prodrugs of (2R)-2-propyloctanoic acid for the treatment of stroke
|
|
EP1816912A4
(en)
|
2004-11-23 |
2008-09-10 |
Merck & Co Inc |
TREATMENT OF APOPLEXY WITH INVERSE HISTAMINE H3 AGONISTS OR HISTAMINE H3 ANTAGONISTS
|
|
US20060111416A1
(en)
|
2004-11-24 |
2006-05-25 |
Lane Charlotte A L |
Octahydropyrrolo[3,4-C]pyrrole derivatives
|
|
US20070224662A1
(en)
|
2004-12-17 |
2007-09-27 |
Jun Luo |
Post-translational modification of proteins in cell-free expression systems
|
|
PE20061155A1
(es)
|
2004-12-24 |
2006-12-16 |
Boehringer Ingelheim Int |
Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas
|
|
US20060154939A1
(en)
|
2004-12-24 |
2006-07-13 |
Boehringer Ingelheim International Gmbh |
Medicaments for the Treatment or Prevention of Fibrotic Diseases
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
US7939536B2
(en)
|
2004-12-28 |
2011-05-10 |
Aska Pharmaceutical Co., Ltd. |
Pyrimidinylisoxazole derivatives
|
|
US20060178388A1
(en)
|
2005-02-04 |
2006-08-10 |
Wrobleski Stephen T |
Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
|
|
CN101128453A
(zh)
|
2005-02-28 |
2008-02-20 |
默克勒有限公司 |
2-亚磺酰基-和2-磺酰基-取代的咪唑衍生物和它们作为细胞因子抑制剂的用途
|
|
US7759337B2
(en)
|
2005-03-03 |
2010-07-20 |
Amgen Inc. |
Phthalazine compounds and methods of use
|
|
MY145343A
(en)
|
2005-03-25 |
2012-01-31 |
Glaxo Group Ltd |
Novel compounds
|
|
PE20061193A1
(es)
|
2005-03-25 |
2006-12-02 |
Glaxo Group Ltd |
DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
|
|
US7423042B2
(en)
|
2005-03-25 |
2008-09-09 |
Glaxo Group Limited |
Compounds
|
|
US20060235020A1
(en)
|
2005-04-18 |
2006-10-19 |
Soojin Kim |
Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
|
|
WO2006122230A1
(en)
|
2005-05-11 |
2006-11-16 |
Array Biopharma Inc. |
P38 inhibitors and methods of use thereof
|
|
US20090074676A1
(en)
|
2005-05-23 |
2009-03-19 |
Smithkline Beecham Corporation |
Inhibition of p38 MAPK For Treatment Of Obesity
|
|
GB0512429D0
(en)
|
2005-06-17 |
2005-07-27 |
Smithkline Beecham Corp |
Novel compound
|
|
US20070032506A1
(en)
|
2005-07-02 |
2007-02-08 |
Peter Giannousis |
Crystalline forms of (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride
|
|
US7473784B2
(en)
|
2005-08-01 |
2009-01-06 |
Bristol-Myers Squibb Company |
Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
|
|
US20090088458A1
(en)
|
2005-08-02 |
2009-04-02 |
Meissner Robert S |
N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators
|
|
CA2618614A1
(en)
|
2005-08-12 |
2007-02-22 |
Merck & Co., Inc. |
Heterobicyclic compounds useful as p38 kinase inhibiting agents
|
|
WO2007024754A1
(en)
|
2005-08-22 |
2007-03-01 |
Amgen Inc. |
Bis-aryl urea compounds for the treatment of protein kinase-mediated diseaes
|
|
KR101011958B1
(ko)
|
2005-08-25 |
2011-01-31 |
에프. 호프만-라 로슈 아게 |
ｐ38 ＭＡＰ 키나아제 저해제로서의 융합형 피라졸
|
|
CN101243051A
(zh)
|
2005-08-25 |
2008-08-13 |
霍夫曼-拉罗奇有限公司 |
p38 MAP激酶抑制剂及使用它的方法
|
|
KR101011956B1
(ko)
|
2005-08-25 |
2011-01-31 |
에프. 호프만-라 로슈 아게 |
Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법
|
|
BRPI0614884A2
(pt)
|
2005-08-25 |
2011-04-19 |
Hoffmann La Roche |
inibidores de p38 map cinase e métodos para uso dos mesmos
|
|
KR20080039438A
(ko)
|
2005-08-25 |
2008-05-07 |
에프. 호프만-라 로슈 아게 |
Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법
|
|
WO2007026950A1
(en)
|
2005-09-01 |
2007-03-08 |
Astellas Pharma Inc. |
Pyridazinone derivatives used for the treatment of pain
|
|
JP4221447B1
(ja)
|
2005-09-21 |
2009-02-12 |
ファイザー・リミテッド |
ムスカリン様受容体アンタゴニストとしてのカルボキサミド誘導体
|
|
JP2009509969A
(ja)
|
2005-09-26 |
2009-03-12 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体モジュレーターとしてのｎ−（４−オキソ−３，４−ジヒドロキナゾリン−２−イル）ブタンアミド
|
|
WO2007045989A1
(en)
|
2005-10-20 |
2007-04-26 |
Pfizer Limited |
Pyridyl derivatives useful as h3 ligands
|
|
PE20070795A1
(es)
|
2005-10-28 |
2007-08-24 |
Lilly Co Eli |
Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
|
|
TW200800194A
(en)
|
2005-10-28 |
2008-01-01 |
Lilly Co Eli |
Kinase inhibitors
|
|
WO2007056016A2
(en)
|
2005-11-02 |
2007-05-18 |
Kemia, Inc. |
Bisamide cytokine inhibitors
|
|
CA2624625A1
(en)
|
2005-11-04 |
2007-05-10 |
Pfizer Limited |
Tetrahydronaphthyridine derivative
|
|
JP2009514851A
(ja)
|
2005-11-08 |
2009-04-09 |
ランバクシー ラボラトリーズ リミテッド |
（３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
|
|
PE20100743A1
(es)
|
2005-11-15 |
2010-11-25 |
Glaxo Group Ltd |
Nuevos procedimientos y formulaciones
|
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
|
WO2007075896A2
(en)
|
2005-12-22 |
2007-07-05 |
Kemia, Inc. |
Heterocyclic cytokine inhibitors
|
|
WO2007084391A2
(en)
|
2006-01-18 |
2007-07-26 |
Amgen Inc. |
Thiazole compounds as protein kinase b ( pkb) inhibitors
|
|
RS52298B
(sr)
|
2006-01-31 |
2012-12-31 |
Array Biopharma Inc. |
Inhibitori kinaze i postupak njihove upotrebe
|
|
US20090012079A1
(en)
|
2006-02-09 |
2009-01-08 |
Russell Andrew Lewthwaite |
Triazolopyridine Compounds
|
|
CA2640665A1
(en)
|
2006-02-10 |
2007-08-16 |
Pfizer Products Inc. |
Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives
|
|
GB0603684D0
(en)
|
2006-02-23 |
2006-04-05 |
Novartis Ag |
Organic compounds
|
|
CA2644421A1
(en)
|
2006-03-07 |
2007-09-13 |
Vertex Pharmaceuticals Incorporated |
Use of vx-702 for treating rheumatoid arthritis
|
|
KR20080107408A
(ko)
|
2006-03-07 |
2008-12-10 |
브리스톨-마이어스 스큅 컴퍼니 |
키나제 억제제로서 유용한 피롤로트리아진 아닐린 전구약물화합물
|
|
WO2007107828A2
(en)
|
2006-03-20 |
2007-09-27 |
Pfizer Limited |
Amine derivatives
|
|
CA2647949A1
(en)
|
2006-03-29 |
2007-11-08 |
Array Biopharma Inc. |
P38 inhibitors and methods of use thereof
|
|
EP2004631A1
(en)
|
2006-04-12 |
2008-12-24 |
Merck Patent GmbH |
N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
|
|
WO2007124181A2
(en)
|
2006-04-21 |
2007-11-01 |
Amgen Inc. |
Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
|
|
CA2691214A1
(en)
|
2006-06-09 |
2007-12-21 |
Kemia, Inc. |
Therapy using cytokine inhibitors
|
|
EP2034838A4
(en)
|
2006-06-16 |
2012-01-04 |
Glaxo Group Ltd |
NOVEL CONNECTIONS
|
|
GB0612026D0
(en)
|
2006-06-16 |
2006-07-26 |
Smithkline Beecham Corp |
New use
|
|
US20090318424A1
(en)
|
2006-06-16 |
2009-12-24 |
Mauro Corsi |
Novel compounds
|
|
EP2031965A4
(en)
|
2006-06-16 |
2010-06-30 |
Glaxo Group Ltd |
NEW COMPOUNDS
|
|
WO2008001929A1
(en)
|
2006-06-28 |
2008-01-03 |
Aska Pharmaceutical Co., Ltd. |
Treatment agent for inflammatory bowel disease
|
|
EP2036905B1
(en)
|
2006-06-28 |
2012-12-12 |
ASKA Pharmaceutical Co., Ltd. |
Pyridylisoxazole derivative
|
|
WO2008011032A1
(en)
|
2006-07-17 |
2008-01-24 |
Amgen Inc. |
Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
|
|
WO2008013823A2
(en)
|
2006-07-26 |
2008-01-31 |
Scios Inc. |
Co-crystals of (2r-trans)-6-chloro-5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n,1-trimethyl-alpha-oxo-1h-indole-3-acetamide
|
|
CA2659222C
(en)
|
2006-07-28 |
2012-01-31 |
Onconova Therapeutics, Inc. |
Formulations of radioprotective .alpha., .beta. unsaturated aryl sulfones
|
|
PE20080906A1
(es)
|
2006-08-17 |
2008-07-05 |
Kemia Inc |
Derivados heteroarilo como inhibidores de citocina
|
|
WO2008024391A1
(en)
|
2006-08-22 |
2008-02-28 |
Scios Inc. |
Pharmaceutical formulations of an indole-type derivative and related methods of use
|
|
WO2008041095A1
(en)
|
2006-10-04 |
2008-04-10 |
Pfizer Limited |
Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists
|
|
WO2008045393A2
(en)
|
2006-10-11 |
2008-04-17 |
Amgen Inc. |
Imidazo- and triazolo-pyridine compounds and methods of use therof
|
|
AU2007313295A1
(en)
|
2006-10-18 |
2008-04-24 |
Merck Sharp & Dohme Corp. |
2-hydroxy-2-phenyl/thiophenyl propionamides as androgen receptor modulators
|
|
US20100099651A1
(en)
|
2006-10-26 |
2010-04-22 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
US7943617B2
(en)
|
2006-11-27 |
2011-05-17 |
Bristol-Myers Squibb Company |
Heterobicyclic compounds useful as kinase inhibitors
|
|
WO2008071664A1
(en)
|
2006-12-12 |
2008-06-19 |
Smithkline Beecham Corporation |
Nicotinamide derivative used as a p38 kinase inhibitor
|
|
WO2008071665A1
(en)
|
2006-12-12 |
2008-06-19 |
Smithkline Beecham Corporation |
A nicotinamide derivative useful as p38 kinase inhibitor
|
|
ATE556055T1
(de)
|
2006-12-13 |
2012-05-15 |
Pfizer Prod Inc |
Verfahren zur herstellung von 3-(4-(2,4- difluorbenzyloxy)-3-brom-6-methyl- 2-oxopyridin- 1(2h)-yl)-n,4-dimethylbenzamid
|
|
EP2125841A1
(en)
|
2006-12-13 |
2009-12-02 |
Gilead Sciences, Inc. |
Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction
|
|
EP2091952A1
(en)
|
2006-12-19 |
2009-08-26 |
F. Hoffmann-Roche AG |
Pyrazolo ý3, 4 -d¨pyrimidine p38 map kinase inhibitors
|
|
WO2008079857A1
(en)
|
2006-12-20 |
2008-07-03 |
Bristol-Myers Squibb Company |
Crystalline forms of aryl-substituted pyrazole-amide compounds
|
|
WO2008089034A2
(en)
|
2007-01-11 |
2008-07-24 |
Kemia, Inc. |
Cytokine inhibitors
|
|
WO2008098096A1
(en)
|
2007-02-08 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Anti-cytokine heterocyclic compounds
|
|
AU2008215659B2
(en)
|
2007-02-16 |
2012-11-01 |
Aska Pharmaceutical Co., Ltd. |
Pharmaceutical composition comprising microparticle oily suspension
|
|
CA2689042A1
(en)
|
2007-02-16 |
2008-08-28 |
Merck & Co., Inc. |
Compositions and methods for potentiated activity of biologicaly active molecules
|
|
WO2008104473A2
(en)
|
2007-02-28 |
2008-09-04 |
F. Hoffmann-La Roche Ag |
Pyrazolopyriidine derivatives and their use as kinase inhibitors
|
|
KR101120227B1
(ko)
|
2007-03-16 |
2012-03-20 |
화이자 리미티드 |
5-［3-（3-하이드록시페녹시）아제티딘-1-일］-5-메틸-2,2-다이페닐-헥산아마이드의 염산염
|
|
WO2008137176A1
(en)
|
2007-05-07 |
2008-11-13 |
Amgen Inc. |
Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use
|
|
WO2008136948A1
(en)
|
2007-05-07 |
2008-11-13 |
Amgen Inc. |
Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators, process for their preparation, and their pharmaceutical use
|
|
US7919504B2
(en)
|
2007-07-17 |
2011-04-05 |
Amgen Inc. |
Thiadiazole modulators of PKB
|
|
EP2173728A2
(en)
|
2007-07-17 |
2010-04-14 |
Amgen Inc. |
Heterocyclic modulators of pkb
|
|
US7943658B2
(en)
|
2007-07-23 |
2011-05-17 |
Bristol-Myers Squibb Company |
Indole indane amide compounds useful as CB2 agonists and method
|
|
WO2009015000A1
(en)
|
2007-07-25 |
2009-01-29 |
Array Biopharma Inc. |
Pyrazole urea derivatives used as kinase inhibitors
|
|
EP2200969A2
(en)
|
2007-09-14 |
2010-06-30 |
Pfizer Limited |
Novel compounds active as muscarinic receptor antagonists
|
|
WO2009038784A1
(en)
|
2007-09-21 |
2009-03-26 |
Amgen Inc. |
Triazole fused heteroaryl compounds as p38 kinase inhibitors
|
|
JP4686650B2
(ja)
|
2007-11-30 |
2011-05-25 |
ファイザー・リミテッド |
新規なグルココルチコイド受容体アゴニスト
|
|
GB0724258D0
(en)
|
2007-12-12 |
2008-01-30 |
Glaxo Group Ltd |
Novel combinations
|
|
WO2009074518A1
(en)
|
2007-12-12 |
2009-06-18 |
Glaxo Group Limited |
Combinations of prolinamide p2x7 modulators with further therapeutic agents
|
|
WO2009078992A1
(en)
|
2007-12-17 |
2009-06-25 |
Amgen Inc. |
Linear tricyclic compounds as p38 kinase inhibitors
|
|
US20110166154A1
(en)
|
2008-01-25 |
2011-07-07 |
Bristol-Myers Squibb Company |
Identification of predictive markers of response to dasatinib in human colon cancer
|
|
US20110203586A1
(en)
|
2008-02-20 |
2011-08-25 |
Boehringer Ingelheim International Gmbh |
Powder Inhalers
|
|
US8367671B2
(en)
|
2008-03-21 |
2013-02-05 |
Amgen Inc. |
Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents
|
|
JP2009263234A
(ja)
|
2008-04-21 |
2009-11-12 |
Ranbaxy Lab Ltd |
ホスホジエステラーゼタイプｉｖ阻害剤の組成物
|
|
AR072008A1
(es)
|
2008-06-13 |
2010-07-28 |
Merck & Co Inc |
Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
|
|
WO2009155389A1
(en)
|
2008-06-20 |
2009-12-23 |
Bristol-Myers Squibb Company |
Triazolopyridine compounds useful as kinase inhibitors
|
|
CN102131805A
(zh)
|
2008-06-20 |
2011-07-20 |
百时美施贵宝公司 |
用作激酶抑制剂的咪唑并吡啶和咪唑并吡嗪化合物
|
|
WO2009158446A2
(en)
|
2008-06-25 |
2009-12-30 |
Bristol-Myers Squibb Company |
Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, method of preparation and use thereof
|
|
WO2009158450A1
(en)
|
2008-06-25 |
2009-12-30 |
Bristol-Myers Squibb Company |
Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, preparation and use thereof
|
|
US8263623B2
(en)
|
2008-07-11 |
2012-09-11 |
Pfizer Inc. |
Triazol derivatives useful for the treatment of diseases
|
|
WO2010007561A1
(en)
|
2008-07-15 |
2010-01-21 |
Pfizer Limited |
Novel compounds active as muscarinic receptor antagonists
|
|
AU2009272303B2
(en)
|
2008-07-15 |
2011-12-22 |
Pfizer Limited |
Novel compounds active as muscarinic receptor antagonists
|
|
EP2334673A1
(en)
|
2008-08-29 |
2011-06-22 |
Amgen Inc. |
PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
|
|
US8455495B2
(en)
|
2008-08-29 |
2013-06-04 |
Amgen Inc. |
Pyridazino-pyridinone compounds and methods of use
|
|
WO2010038428A1
(ja)
|
2008-09-30 |
2010-04-08 |
武田薬品工業株式会社 |
タキサン系抗がん剤の置き換え薬
|
|
EP2206534A1
(de)
|
2008-10-09 |
2010-07-14 |
c-a-i-r biosciences GmbH |
Dibenzocycloheptanonderivate und pharmazeutische Mittel, welche diese Verbindungen enthalten
|
|
US8772481B2
(en)
|
2008-10-10 |
2014-07-08 |
Amgen Inc. |
Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof
|
|
US8497269B2
(en)
|
2008-10-10 |
2013-07-30 |
Amgen Inc. |
Phthalazine compounds as p38 map kinase modulators and methods of use thereof
|
|
EP2387570A1
(en)
|
2009-01-15 |
2011-11-23 |
Amgen, Inc |
Fluoroisoquinoline substituted thiazole compounds and methods of use
|
|
EP2393492A1
(en)
|
2009-02-09 |
2011-12-14 |
Boehringer Ingelheim International GmbH |
New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
EP2396302A2
(en)
|
2009-02-13 |
2011-12-21 |
Vertex Pharmceuticals Incorporated |
Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides)
|
|
JP2012518003A
(ja)
|
2009-02-13 |
2012-08-09 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
２−（２，４−ジフルオロフェニル）−６−（１−（２，６−ジフルオロフェニル）ウレイド）ニコチンアミドの固体形態
|
|
CA2752693A1
(en)
|
2009-02-17 |
2010-08-26 |
Chiesi Farmaceutici S.P.A. |
Triazolopyridine derivatives as p38 map kinase inhibitors
|
|
GB0902648D0
(en)
|
2009-02-17 |
2009-04-01 |
Argenta Discovery Ltd |
Pharmaceutical compounds and compositions
|
|
US20120035177A1
(en)
|
2009-04-16 |
2012-02-09 |
Bristol-Myers Squibb Company |
Tablet formulation for p38 inhibitor and method
|
|
JP5620979B2
(ja)
|
2009-05-05 |
2014-11-05 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
Ｐ３８キナーゼ阻害剤
|
|
US20120157500A1
(en)
|
2009-08-24 |
2012-06-21 |
Weikang Tao |
Jak inhibition blocks rna interference associated toxicities
|
|
EP3011970A3
(en)
|
2009-10-22 |
2016-06-08 |
F. Hoffmann-La Roche AG |
Modulation of axon degeneration
|
|
WO2011063076A1
(en)
|
2009-11-19 |
2011-05-26 |
Itherx Pharmaceuticals, Inc. |
Methods of treating hepatitis c virus with oxoacetamide compounds
|
|
WO2011083387A1
(en)
|
2010-01-07 |
2011-07-14 |
Pfizer Limited |
Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
|
|
CA2792883A1
(en)
|
2010-03-24 |
2011-09-29 |
Onconova Therapeutics, Inc. |
Compositions and methods for prevention and treatment of wounds
|
|
KR101838764B1
(ko)
|
2010-03-26 |
2018-03-14 |
온코노바 테라퓨틱스, 인코포레이티드 |
(ｅ)-4-카복시스티릴-4-클로로벤질설폰의 개선된 안정한 수성 제형
|
|
GB201009731D0
(en)
|
2010-06-10 |
2010-07-21 |
Pulmagen Therapeutics Inflamma |
Kinase inhibitors
|
|
AU2011273931B2
(en)
|
2010-06-28 |
2015-04-23 |
Merck Patent Gmbh |
2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
|
|
US8846931B2
(en)
|
2010-07-05 |
2014-09-30 |
Merck Patent Gmbh |
Bipyridyl derivatives
|
|
WO2012031057A1
(en)
|
2010-09-01 |
2012-03-08 |
Bristol-Myers Squibb Company |
Bms- 582949 for the treatment of resistant rheumatic disease
|
|
RU2013129860A
(ru)
|
2010-11-29 |
2015-01-10 |
Дженентек, Инк. |
Способы выявления нейродегенеративных заболеваний или нарушений
|
|
TWI410425B
(zh)
|
2010-12-03 |
2013-10-01 |
Lilly Co Eli |
唑并［５，４－ｂ］吡啶－５－基化合物
|
|
ES2542647T3
(es)
|
2011-03-09 |
2015-08-07 |
Merck Patent Gmbh |
Derivados de pirido[2,3 b]pirazina y sus usos terapéuticos
|
|
DK3081568T3
(da)
|
2011-05-09 |
2020-02-24 |
Eip Pharma Llc |
Sammensætninger og fremgangsmåder til behandling af alzheimers sygdom
|
|
ME02297B
(me)
|
2011-06-10 |
2016-02-20 |
Chiesi Farm Spa |
Jedinjenja koja imaju aktivnost antagonista muskarinskih receptora i agonist beta2 adrenergičnog receptora
|
|
EP3111937B1
(en)
|
2011-07-08 |
2020-06-17 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Medicament for treatment of liver cancer
|
|
AP3881A
(en)
|
2011-11-11 |
2016-10-31 |
Lilly Co Eli |
Combination therapy for ovarian cancer
|
|
WO2013086002A1
(en)
|
2011-12-05 |
2013-06-13 |
Cellworks Research India Private Limited |
Compositions, process of preparation of said compositions and method of treating cancer
|
|
US9458154B2
(en)
|
2011-12-09 |
2016-10-04 |
Chiesi Farmaceutici S.P.A. |
Kinase inhibitors
|
|
MY167216A
(en)
|
2011-12-09 |
2018-08-14 |
Chiesi Farm Spa |
Kinase inhibitors
|
|
UA115320C2
(uk)
|
2011-12-09 |
2017-10-25 |
К'Єзі Фармачеутічі С.П.А. |
Інгібітори кінази
|
|
KR102668696B1
(ko)
|
2012-01-12 |
2024-05-29 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
SI2819998T1
(sl)
|
2012-03-01 |
2022-07-29 |
Array Biopharma Inc. |
Kristalinske oblike 1-(3-tert-butil-1-P-tolil-1H-pirazol-5-il)-3- (5-fluoro-2-(1-(2-hidroksietil)-1H-indazol-5-iloksi)benzil)urea hidroklorida
|
|
WO2013139809A1
(en)
|
2012-03-20 |
2013-09-26 |
Novartis Ag |
Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
|
|
CN104271566B
(zh)
|
2012-05-22 |
2017-05-31 |
霍夫曼-拉罗奇有限公司 |
取代的联吡啶胺及其用途
|
|
CN104684546A
(zh)
*
|
2012-06-07 |
2015-06-03 |
哈佛大学校长及研究员协会 |
用于药物靶向的纳米疗法
|
|
RU2014152454A
(ru)
|
2012-07-17 |
2016-09-10 |
ГЛАКСОСМИТКЛАЙН ЭлЭлСи |
Производное никотинамида в лечении острого коронарного синдрома
|
|
GB201214750D0
(en)
|
2012-08-17 |
2012-10-03 |
Respivert Ltd |
Compounds
|
|
US20150225373A1
(en)
|
2012-08-29 |
2015-08-13 |
Respivert Limited |
Kinase inhibitors
|
|
EP2890460B1
(en)
|
2012-08-29 |
2017-02-22 |
Respivert Limited |
Kinase inhibitors
|
|
GB201215357D0
(en)
|
2012-08-29 |
2012-10-10 |
Respivert Ltd |
Compounds
|
|
US9783556B2
(en)
|
2012-08-29 |
2017-10-10 |
Respivert Limited |
Kinase inhibitors
|
|
US9155747B2
(en)
|
2012-09-13 |
2015-10-13 |
Chiesi Farmaceutici S.P.A. |
Isoxazolidine derivatives
|
|
US9732063B2
(en)
|
2012-11-16 |
2017-08-15 |
Respivert Limited |
Kinase inhibitors
|
|
MX2015006457A
(es)
|
2012-11-30 |
2015-08-14 |
Hoffmann La Roche |
Inhibidores de la tirosina cinasa de bruton.
|
|
US9370527B2
(en)
|
2012-12-28 |
2016-06-21 |
The Regents Of The University Of Michigan |
Amelioration of intestinal fibrosis and treatment of Crohn's disease
|
|
WO2014134313A1
(en)
|
2013-02-27 |
2014-09-04 |
Array Biopharma Inc. |
Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof
|
|
WO2014140582A1
(en)
|
2013-03-14 |
2014-09-18 |
Respivert Limited |
Kinase inhibitors
|
|
GB201305714D0
(en)
|
2013-03-28 |
2013-05-15 |
Ucl Business Plc |
Method
|
|
AU2014248455B2
(en)
*
|
2013-04-01 |
2018-12-06 |
Pulmatrix Operating Company, Inc. |
Tiotropium dry powders
|
|
AU2014246866B2
(en)
|
2013-04-02 |
2018-05-10 |
Oxular Acquisitions Limited |
Kinase inhibitor
|
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
|
RU2015151886A
(ru)
|
2013-06-06 |
2017-06-08 |
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. |
Ингибиторы киназ
|
|
WO2014194956A1
(en)
|
2013-06-06 |
2014-12-11 |
Chiesi Farmaceutici S.P.A. |
Derivatives of [1, 2, 4] triazolo [4, 3 - a] pyridine as p38 - map kinase inhibitors
|
|
EP3004098B1
(en)
|
2013-06-06 |
2017-08-09 |
Chiesi Farmaceutici S.p.A. |
Kinase inhibitors
|
|
CA2917277A1
(en)
*
|
2013-07-10 |
2015-01-15 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Losmapimod for use in treating glomerular disease
|
|
WO2015006752A1
(en)
|
2013-07-12 |
2015-01-15 |
The Regents Of The University Of California |
Combination therapies for malaria
|
|
US9814728B2
(en)
|
2013-09-20 |
2017-11-14 |
Saint Louis University |
Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi)
|
|
WO2015072580A1
(ja)
*
|
2013-11-14 |
2015-05-21 |
学校法人同志社 |
細胞増殖促進または細胞障害抑制による角膜内皮治療薬
|
|
MX2016008110A
(es)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
|
|
CA2934199A1
(en)
|
2013-12-20 |
2015-06-25 |
Respivert Limited |
Urea derivatives useful as kinase inhibitors
|
|
PT3357919T
(pt)
|
2014-02-14 |
2020-02-20 |
Respivert Ltd |
Compostos heterocíclicos aromáticos como compostos antiinflamatórios
|
|
KR20160115936A
(ko)
|
2014-02-19 |
2016-10-06 |
하. 룬드벡 아크티에셀스카브 |
알츠하이머병의 치료를 위한 bace1 저해제로서의 2-아미노-3,5,5-트리플루오로-3,4,5,6-테트라하이드로피리딘
|
|
CN107073121A
(zh)
|
2014-06-13 |
2017-08-18 |
基因泰克公司 |
治疗及预防癌症药物抗性的方法
|
|
WO2015191996A1
(en)
|
2014-06-13 |
2015-12-17 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
EP3166610B1
(en)
|
2014-07-09 |
2022-11-02 |
Eip Pharma, LLC |
Methods for treating neurologic disorders
|
|
MA40774A
(fr)
|
2014-10-01 |
2017-08-08 |
Respivert Ltd |
Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
|
|
EP3201189A1
(en)
|
2014-10-01 |
2017-08-09 |
Respivert Limited |
N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors
|
|
US20180117110A1
(en)
|
2014-10-03 |
2018-05-03 |
The Walter And Eliza Hall Institute Of Medical Research |
Method of treating cancer
|
|
WO2016066687A1
(en)
|
2014-10-30 |
2016-05-06 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Losmapimod for treating copd
|
|
WO2016114655A1
(en)
*
|
2015-01-12 |
2016-07-21 |
Ry Pharma B.V. |
Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
|
|
US10538763B2
(en)
*
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
|
ES2918975T3
(es)
|
2015-02-06 |
2022-07-21 |
Association Inst De Myologie |
Tratamiento de la distrofia facioescapulohumeral
|
|
TWI703138B
(zh)
|
2015-02-12 |
2020-09-01 |
義大利商吉斯藥品公司 |
具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
|
|
CN107406462B
(zh)
|
2015-03-09 |
2020-11-10 |
豪夫迈·罗氏有限公司 |
三环dlk抑制剂及其用途
|
|
WO2016154329A2
(en)
*
|
2015-03-24 |
2016-09-29 |
The Trustees Of The University Of Pennsylvania |
P38 map kinase inhibitors for treating friedreich's ataxia
|
|
JP2016193870A
(ja)
|
2015-04-01 |
2016-11-17 |
国立大学法人広島大学 |
慢性骨髄性白血病治療剤
|
|
US9968604B2
(en)
|
2015-04-16 |
2018-05-15 |
Chiesi Farmaceutici S.P.A. |
Chromene derivatives as phoshoinositide 3-kinases inhibitors
|
|
CN107921106B
(zh)
*
|
2015-05-20 |
2023-09-08 |
住友制药株式会社 |
Wt1抗原肽和免疫调节剂的组合用途
|
|
AU2016272089B2
(en)
*
|
2015-06-03 |
2021-02-18 |
Triastek, Inc. |
Dosage forms and use thereof
|
|
WO2016198698A2
(en)
|
2015-06-12 |
2016-12-15 |
Cnic Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii |
P38 inhibitors for the treatment and prophylaxis of liver cancer
|
|
RU2722149C1
(ru)
|
2015-09-14 |
2020-05-27 |
Пфайзер Инк. |
Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
|
|
WO2017075013A1
(en)
|
2015-10-26 |
2017-05-04 |
Eip Pharma, Llc |
Methods and compositions for recovery from stroke
|
|
US9427439B1
(en)
|
2015-10-26 |
2016-08-30 |
Eip Pharma, Llc |
Methods and compositions for recovery from stroke
|
|
WO2017093208A1
(en)
|
2015-12-03 |
2017-06-08 |
Chiesi Farmaceutici S.P.A. |
Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
|
|
WO2017108736A1
(en)
|
2015-12-23 |
2017-06-29 |
Chiesi Farmaceutici S.P.A. |
N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
|
|
JPWO2017110093A1
(ja)
|
2015-12-24 |
2018-10-11 |
学校法人同志社 |
ＴＧＦ−βシグナルに起因する障害を治療または予防するための医薬およびその応用
|
|
US20190125735A1
(en)
|
2015-12-29 |
2019-05-02 |
Board Of Regents, The University Of Texas System |
Inhibition of p38 mapk for the treatment of cancer
|
|
AU2017213796A1
(en)
*
|
2016-02-01 |
2018-09-20 |
President And Fellows Of Harvard College |
Small molecules for mouse satellite cell proliferation
|
|
WO2017134053A1
(en)
|
2016-02-04 |
2017-08-10 |
Chiesi Farmaceutici S.P.A. |
Pyrazole derivatives as phosphoinositide 3-kinases inhibitors
|
|
ES2866883T3
(es)
|
2016-06-08 |
2021-10-20 |
Support Venture Gmbh |
Combinaciones farmacéuticas para el tratamiento del cáncer
|
|
GB201611712D0
(en)
|
2016-07-02 |
2016-08-17 |
Hvivo Services Ltd |
Methods and compounds for the treatment or prevention of severe or persistent influenza
|
|
AU2018221891B2
(en)
|
2017-02-15 |
2023-05-25 |
The University Of Melbourne |
A method of treatment
|
|
BR112020006677A2
(pt)
|
2017-10-05 |
2020-10-06 |
Fulcrum Therapeutics, Inc. |
uso de inibidores p38 para reduzir a expressão de dux4
|
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
|
US20200297696A1
(en)
|
2017-11-21 |
2020-09-24 |
Saint Louis University |
P38 inhibitors for the treatment of fshd
|
|
WO2020106876A2
(en)
|
2018-11-20 |
2020-05-28 |
Fulcrum Therapeutics, Inc. |
Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease
|
|
WO2020132004A1
(en)
*
|
2018-12-20 |
2020-06-25 |
Saint Louis University |
Bet inhibitors for modulating dux4 expression in fshd
|
|
WO2020190754A1
(en)
|
2019-03-15 |
2020-09-24 |
Fulcrum Therapeutics, Inc. |
Macrocyclic azolopyridine derivatives as eed and prc2 modulators
|
|
CA3189065A1
(en)
*
|
2020-09-11 |
2022-03-17 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
|